Search Results - david+karambizi

3 Results

Sort By:

Inhibition of the Egr2 promoter Antisense RNA with oligonucleotide GapmeRs as novel RNA therapy for human neuropathies

Overview Peripheral neuropathy can be caused by trauma, disease, or chemotherapy. We have developed sustained-release formulations that treat human neuropathies by prompting remyelination of the damaged nerves. The formulations are delivered by injection at the site of nerve damage, using a polymeric gel. Market Opportunity Peripheral nerve damage...

Published: 6/6/2024 | Inventor(s): Nikolaos (Nikos) Tapinos, David Karambizi, Margot Moreno

Keywords(s):

Category(s): Neurodegenerative Disease

Inhibition of FTO with Entacapone to Treat Glioblastoma

Overview Glioblastoma is one of the most aggressive and lethal human tumors. We are investigating the use of an FDA-approved drug, Entacapone, to treat glioma tumors. Market Opportunity Glioblastoma, one of the most aggressive forms of cancer, has a survival rate of only 14–15 months after diagnosis. There is an urgent need for effective therapies...

Published: 10/15/2022 | Inventor(s): Nikolaos (Nikos) Tapinos, John Zepecki, David Karambizi

Keywords(s):

Category(s): Oncology, Therapeutics

HDAC-7 as novel therapeutic target for human glioblastoma

Overview Glioblastoma is one of the most aggressive and lethal human tumors. We have identified histone deacetylase 7 (HDAC-7) as a potential therapeutic target, a crucial first step toward development of an effective treatment for glioblastoma. Market Opportunity Glioblastoma is the most malignant and aggressive primary brain tumor, with a survival...

Published: 10/15/2022 | Inventor(s): Nikolaos (Nikos) Tapinos, Ola Hassan, David Karambizi

Keywords(s):

Category(s): Therapy Targets, Oncology